Nyhet -

Stem cell product XSTEM in clinical studies

The Swedish biopharma company Xintela is receiving a lot of attention for its stem cell product platform XSTEMÒand its stem cell therapies in development.

XSTEM is now in clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers.

Over the last several years Xintela has worked extensively on preclinical development in three core areas: osteoarthritis, difficult-to-heal leg ulcers and ARDS (Acute respiratory distress syndrome). The company has now entered into clinical development with its patented stem cell product XSTEM which consists of integrin a10b1-selected mesenchymal stem cells from donated adipose tissue.

Clinical development in knee osteoarthritis and difficult-to-heal venous leg ulcers

Xintela has started its first clinical study (Phase I/IIa) in Australia in patients with knee osteoarthritis. The main goal is to show that XSTEM is safe, but also to obtain preliminary results showing that the product has DMOAD (Disease Modifying Osteoarthritis Drug) properties and can slow cartilage and joint breakdown as well as regenerate damaged articular cartilage and improve joint function.

A clinical study with XSTEM in patients with difficult-to-heal venous leg ulcers (Phase I/IIa) is scheduled to start after the summer. The study will be conducted in collaboration with Linköping University Hospital in Sweden and is largely financed by grants from Vinnova.

Preclinical studies have shown that XSTEM is both safe and effective and has the ability to regenerate damaged cartilage and skin wounds in relevant animal models. Today, there are no treatments available that can regenerate and heal Difficult-to-heal leg ulcers or damaged cartilage in osteoarthritis. XSTEM thus holds great potential to be a breakthrough in the treatment of these diseases.

“What is unique about our patented stem cell product XSTEM is our stem cell selection technology that allows for the generation of a homogenous and high-quality product which likely improves both safety and efficacy compared to other stem cell technologies. The stem cell selection step also assures reproducibility between different stem cell preparations, which is a great regulatory advantage”, says CEO Evy Lundgren-Åkerlund.

XSTEM has also been evaluated in a preclinical model for ARDS; a life-threatening form of acute lung failure, which can occur as a result of, for example, blood poisoning and pneumonia and can also affect seriously ill Covid-19 patients. The studies which were performed in collaboration with Skåne University hospital and Lund University

showed significant therapeutic effect of XSTEM including less lung tissue damage and improved lung function.

“There is no treatment available for this terrible lung complication and the mortality is very high. We are therefore very excited about the promising therapeutic effect of XSTEM in the preclinical ARDS model and we are now looking for a partner to take the step towards clinical studies with XSTEM to treat ARDS patients” says Evy Lundgren-Åkerlund.

Manufacturer of ATMPs

Last year, Xintela received permission from the Medical Products Agency to manufacture XSTEM and other advanced therapies in the company’s own GMP-facility. The manufacturing facility is fully operational and the team has successfully produced XSTEM for the clinical studies of both osteoarthritis and difficult-to-heal leg ulcers.

“It was an important strategic decision to build our own GMP-facility to manufacture our stem cell products in-house. This gives us full control of the product development, full flexibility and a highly cost-effective production solution”, continues Evy Lundgren-Åkerlund.

For Xintela, their stem cell product XSTEM and GMP-facility are paving the way for more opportunities not just for them, but for many partners within the wider medical community.

“Our patented and highly competitive stem cell product XSTEM, combined with our own GMP manufacturing capability, is an attractive concept in partnering discussions. Our GMP-manufacturing competence also opens up the possibility to act as contract manufacturer to support process development and manufacturing of other ATMPs, by which new revenue opportunities can be created”, concludes Evy Lundgren-Åkerlund.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

Relaterad media

Relaterat innehåll

  • Novel treatments for aggressive cancer based on a unique target

    The discovery of the unique target integrin α10β1 may change the outcome of cancer treatment for thousands of patients across the world. Tumor-targeting antibodies for the treatment of aggressive cancers are currently being developed by Targinta, a subsidiary of biopharma company Xintela in Lund.
    Targinta is the oncology subsidiary of the stem cell company Xintela. Both Xintela and Targinta ar

  • The uniqueness of Medicon Valley Alliance

    Medicon Valley Alliance (MVA) is a non-profit membership organisation in the Danish-Swedish life science cluster Medicon Valley. They also have the distinction of being the only bi-national cluster region in the Nordics.
    All cluster formations within Life Science collaborate with other actors nationally and internationally, but MVA has built an entire life science cluster across two leading lif

  • New MDR and IVDR provide both challenges and opportunities

    Most pharmaceutical and medical device developers need guidance to come to terms with new and changing regulations. They also need competent hands-on support in times of high workload. Not least, concerning the new regulations of medical technology products, MDR, and the new IVDR for in-vitro diagnostics.
    Pharmaceutical companies, In-Vitro Diagnostic Companies and Medical Device developers are

  • Very promising clinical results in new treatment of varicose veins

    Established in 2013 by Dr Michael Åkesson, the company MedVasc was created to help his pursuit on improving the procedure of minimally invasive treatment in the condition of varicose vein. Michael has a long experience in developing and testing new catheters for endovascular techniques.
    The earning potential of Solutio (which was patented in 2015) paved the way for additional investment and cre

  • Providing a fast lane to preclinical development

    The past year has been very productive at the relatively small Contract Research Organisation (CRO) Redoxis. Being specialised in preclinical drug development and efficacy evaluation models, Redoxis offers invaluable support to any pharmaceutical drug developer at the very early stages.
    “A lot of CROs tend to focus on the later phases of development, even if they still retain a preclinical app

Fyll i din epostadress för att följa Affärstidningen Näringsliv

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Affärstidningen Näringsliv.

Okej